NEW YORK — Applied Cells said on Tuesday that it has signed an agreement to jointly market its MARS cell preparation and isolation technologies with S2 Genomics' Singulator 100 solid tissue dissociation system.
Applied Cells' MARS Acoustics technology enables label-free immune cell separation from lysed cell debris, dead cells, and other small particles, according to the Santa Clara, California-based company. Its MARS Magnetic technology separates cells bound to magnetic beads from cells unbound to magnetic beads in flow channels, without the need for dedicated columns.
S2's Singulator 100 system automates the processing of solid tissue samples into suspensions of single cells or nuclei with high yields and from small samples.
Financial and other terms of the marketing deal were not disclosed.
"Our joint marketing with S2 Genomics provides a powerful combination of Singulator and MARS solutions to the field of tumor biology," Applied Cells Chief Commercial Officer Janette Phi said in a statement.
In late 2020, Livermore, California-based S2 inked a Canadian distribution deal for the Singulator 100 system with D-Mark Biosciences.